Search

Your search keyword '"Weber, J.S."' showing total 117 results
Start Over Author "Weber, J.S."
117 results on '"Weber, J.S."'

3. 119O Long-term efficacy and patterns of response of lifileucel tumor-infiltrating lymphocyte (TIL) cell therapy in patients with advanced melanoma: A 4-year analysis of the C-144-01 study

Author

Medina, T., primary, Chesney, J.A., additional, Whitman, E., additional, Kluger, H., additional, Thomas, S., additional, Sarnaik, A., additional, Kirkwood, J.M., additional, Larkin, J., additional, Weber, J.S., additional, Hamid, O., additional, Wermke, M., additional, Finckenstein, F. Graf, additional, Chou, J., additional, Gastman, B., additional, Sulur, G., additional, Wu, X., additional, Shi, W., additional, and Domingo-Musibay, E., additional

Published
2023
Full Text
View/download PDF

7. 35MO Number of IL-2 doses and clinical outcomes of tumor-infiltrating lymphocyte (TIL) cell therapy: Post hoc analysis of the C-144-01 trial of lifileucel in patients with advanced melanoma

Author

Hassel, J.C., primary, Sarnaik, A., additional, Chesney, J., additional, Medina, T., additional, Hamid, O., additional, Thomas, S., additional, Wermke, M., additional, Domingo-Musibay, E., additional, Kirkwood, J.M., additional, Larkin, J., additional, Weber, J.S., additional, Arance Fernandez, A.M., additional, Rodriguez, J.F., additional, Thomas, I., additional, Corrie, P.G., additional, Gontcharova, V., additional, Wu, X., additional, Shi, W., additional, and Kluger, H., additional

Published
2022
Full Text
View/download PDF

9. 844P Efficacy and safety of lifileucel, an investigational autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma previously treated with anti-LAG3 antibody

Author

Larkin, J., primary, Dalle, S., additional, Sanmamed, M.F., additional, Wilson, M., additional, Hassel, J.C., additional, Kluger, H., additional, Orloff, M., additional, Weber, J.S., additional, Graf Finckenstein, F., additional, Hari, P., additional, Jagasia, M., additional, Yin, H., additional, Shi, W., additional, Sulur, G., additional, Wu, X., additional, Gontcharova, V., additional, and Lewis, K., additional

Published
2022
Full Text
View/download PDF

10. 788O Association of pre-treatment ctDNA with disease recurrence and clinical and translational factors in patients with stage IIIB-D/IV melanoma treated with adjuvant immunotherapy (CheckMate 915)

Author

Long, G.V., primary, Desai, K., additional, Tang, T., additional, Weber, J.S., additional, Dolfi, S., additional, Ritchings, C., additional, Huang, S-P., additional, Bolisetty, M., additional, Sausen, M., additional, Del Vecchio, M., additional, Larkin, J., additional, Baden, J., additional, Balli, D., additional, Chang, H., additional, Loffredo, J., additional, Zhang, N., additional, Wind-Rotolo, M., additional, and Tenney, D., additional

Published
2022
Full Text
View/download PDF

16. 1084P PLATForM: Descriptive analysis from a randomised, phase II study of novel spartalizumab combinations in previously treated unresectable/metastatic melanoma

Author

Robert, C., primary, Schadendorf, D., additional, Long, G.V., additional, Ascierto, P., additional, Intagliata, S., additional, Meier, F., additional, van der Veldt, A.A.M., additional, Ribas, A., additional, Weber, J.S., additional, Stenson, L., additional, Solovieff, N., additional, Louveau, A-L., additional, Boran, A.D., additional, Grob, J.J., additional, and Dummer, R., additional

Published
2021
Full Text
View/download PDF

20. 1091P Relapse-free survival with adjuvant dabrafenib/trametinib therapy after relapse on a prior adjuvant checkpoint inhibitor and subsequent surgical resection in patients with BRAF V600-mutated stage III/IV melanoma

Author

Weber, J.S., Haque, W., Markovic, S.N., Salama, A.K.S., Mehmi, I., Sullivan, R.J., Najjar, Y.G., van Akkooi, A.C.J., Menzies, A.M., Long, G.V., Taylor, A.M., Haanen, J.B.A.G., Zijlker, L., Davis, K., Karanth, S., Shah, R., Connolly, L., and Norton, D.

Published
2023
Full Text
View/download PDF

22. Safety & efficacy of lifileucel (LN-144) tumor infiltrating lymphocyte therapy in metastatic melanoma patients after progression on multiple therapies – independent review committee data update

Author

Sarnaik, A. (Amod), Khushalani, N. (Nikhil), Chesney, J. (Jason), Kluger, H. (Harriet), Curti, B. (Brendan), Lewis, K. (Karl), Medina, T. (Theresa), Thomas, S. (Sajeve), Pavlick, A. (Anna), Whitman, E. (Eric), Martin-Algarra, S. (Salvador), Corrie, P. (Pippa), Hamid, O. (Omid), Lutzky, J. (Jose), Olah, J. (Judit), Weber, J.S. (Jeffrey S.), Larkin, J. (James), Shi, W. (Wen), DiTrapani, K. (Kelly), Qin, H. (Harry), Mirgoli, M. (Mariam), Wu, R. (Renee), Takamura, T. (Toshimi), Fardis, M. (Maria), and Kirkwood, J.M. (John M.)

Subjects
Inhibitors, Treatment options, Advanced melanoma, Cell therapy
Abstract

Treatment options are limited for patients with advanced melanoma who have progressed on checkpoint inhibitors and targeted therapies such as BRAF/MEK inhibitors (if BRAF-V600E mutated). Adoptive cell therapy utilizing tumor-infiltrating lymphocytes (TIL) has shown antitumor efficacy with durable responses in heavily pretreated melanoma patients. Safety and efficacy of lifileucel, a centrally manufactured cryopreserved autologous TIL therapy assessed by both investigator and an independent review committee (IRC), are presented.

Published
2020

23. Biological responses to porcine respiratory and reproductive syndrome virus in pigs of two genetic populations

Author

Petry, D.B., Holl, J.W., Weber, J.S., Doster, A.R., Osorio, F.A., and Johnson, R.K.

Subjects
Virus diseases -- Health aspects, Swine -- Health aspects, Genetic research -- Health aspects, Zoology and wildlife conservation
Abstract

One hundred pigs from the NE Index Line (NEI) and 100 Hampshire-Duroc cross pigs (HD) were inoculated intranasally with porcine respiratory and reproductive syndrome virus (PRRSV 97-7895 strain) at 26 d of age to determine whether genetic variation in response to PRRSV exists. An uninfected littermate to each infected pig served as a control. Pigs were from 163 dams and 83 sires. Body weight and rectal temperature were recorded, and blood samples were drawn from each pig on d 0 before inoculation and on d 4, 7, and 14 after inoculation. Pigs were sacrificed on d 14. Lung and bronchial lymph nodes were collected, placed in optimal cutting temperature compound, and frozen at -80[degrees] C. The presence of PRRSV in serum and in lung tissue and bronchial lymph nodes was determined by isolation in cell culture. The presence of antibodies in serum collected on d 14 was determined by a commercial ELISA test. Lung tissue was examined microscopically and scored for incidence and severity of lesions (score of 1 to 3; 1 = no or few lesions, and 3 = severe interstitial pneumonia). Data were analyzed with a mixed model that included random sire and data effects. The interaction of line x treatment was significant (P < 0.001) for weight change and rectal temperature. Uninfected HD pigs gained 0.67 kg more from d 0 to 14 and averaged 0.32[degrees] C higher rectal temperature than uninfected NEI pigs (P < 0.001), whereas infected NEI pigs gained 0.34 kg more and had -0.54[degrees] C lower temperature than infected HD pigs (P < 0.001). Viremic titer (cell culture infectious dose 50%/mL) was greater (P < 0.05) in HD than NEI at d 4 ([10.sup.4.52] VS. [10.sup.422] ), 7 ([10.sup.4.47] vs. [10.sup.3.99] ), and 14 ([10.sup.3.49] vs. [10.sup.3.23] ). Viral titer loads in lung (P = 0.11) and bronchial lymph nodes tended (P = 0.07) to be greater in HD than NEI pigs. Antibody signal-to-positive (S/P) ELISA ratios in infected pigs ranged from 0.18 to 3.38, and 88% had levels [greater than or equal to] 0.40, which is the positive threshold for this ELISA. The S/ P range in uninfected pigs was 0 to 1.11, and 99% had levels [less than or equal to] 0.40. Mean S/P ratio for infected pigs was 0.23 units higher in HD than in NEI (P < 0.001). The HD pigs had a greater incidence of interstitial pneumonia and 0.65 higher mean lesion scores than NEI pigs (P < 0.001). In summary, responses of pigs of the two lines to infection with PRRSV differed, indicating that underlying genetic variation existed. Key Words: Biological Indicators, Genetic Variation, Virus

Published
2005

27. Cooperation between Constitutive and Inducible Chemokines Enables T Cell Engraftment and Immune Attack in Solid Tumors

Author

Dangaj, D. Bruand, M. Grimm, A.J. Ronet, C. Barras, D. Duttagupta, P.A. Lanitis, E. Duraiswamy, J. Tanyi, J.L. Benencia, F. Conejo-Garcia, J. Ramay, H.R. Montone, K.T. Powell, D.J., Jr. Gimotty, P.A. Facciabene, A. Jackson, D.G. Weber, J.S. Rodig, S.J. Hodi, S.F. Kandalaft, L.E. Irving, M. Zhang, L. Foukas, P. Rusakiewicz, S. Delorenzi, M. Coukos, G.

Subjects
stomatognathic diseases, stomatognathic system, parasitic diseases, virus diseases, hemic and immune systems
Abstract

We investigated the role of chemokines in regulating T cell accumulation in solid tumors. CCL5 and CXCL9 overexpression was associated with CD8+ T cell infiltration in solid tumors. T cell infiltration required tumor cell-derived CCL5 and was amplified by IFN-γ-inducible, myeloid cell-secreted CXCL9. CCL5 and CXCL9 coexpression revealed immunoreactive tumors with prolonged survival and response to checkpoint blockade. Loss of CCL5 expression in human tumors was associated with epigenetic silencing through DNA methylation. Reduction of CCL5 expression caused tumor-infiltrating lymphocyte (TIL) desertification, whereas forced CCL5 expression prevented Cxcl9 expression and TILs loss, and attenuated tumor growth in mice through IFN-γ. The cooperation between tumor-derived CCL5 and IFN-γ-inducible CXCR3 ligands secreted by myeloid cells is key for orchestrating T cell infiltration in immunoreactive and immunoresponsive tumors. Dangaj et al. show that tumor cell-expressed CCL5 and macrophage- and DC-expressed CXCL9 are important for the infiltration of T cells into tumors, a process that also requires recognition of tumor antigens by T cells. CCL5 is often epigenetically silenced in tumor cells but can be reactivated by Decitabine. © 2019 Elsevier Inc.

Published
2019

31. A phase II, open-label, randomized, multicenter trial of encorafenib + binimetinib evaluating a standard-dose and a high-dose regimen in patients with BRAFV600-mutant melanoma brain metastasis (MBM) (POLARIS)

Author

Davies, M.A., primary, Weber, J.S., additional, Flaherty, K.T., additional, McArthur, G.A., additional, Reddy, M.B., additional, Golden, A., additional, Culbertson, J.L., additional, Thomas, C.T., additional, Tawbi, H.A., additional, and Long, G.V., additional

Published
2019
Full Text
View/download PDF

32. Adjuvant nivolumab (NIVO) versus ipilimumab (IPI) in resected stage III/IV melanoma: 3-year efficacy and biomarker results from the phase III CheckMate 238 trial

Author

Weber, J.S., primary, Del Vecchio, M., additional, Mandala, M., additional, Gogas, H., additional, Arance, A.M., additional, Dalle, S., additional, Cowey, C.L., additional, Schenker, M., additional, Grob, J.J., additional, Chiarion-Sileni, V., additional, Marquez-Rodas, I., additional, Butler, M.O., additional, Maio, M., additional, Middleton, M.R., additional, Tang, T., additional, Saci, A., additional, De Pril, V., additional, Lobo, M., additional, Larkin, J.M.G., additional, and Ascierto, P.A., additional

Published
2019
Full Text
View/download PDF

33. Traitement adjuvant par nivolumab (NIVO) par rapport à l’ipilimumab (IPI) après résection complète d’un mélanome au stade III/IV : résultats actualisés d’un essai de phase III (CheckMate 238)

Author

Weber, J.S., primary, Mandala, M., additional, Del Vecchio, M., additional, Gogas, H., additional, Arance, A.M., additional, Lance Cowey, C., additional, Dalle, S., additional, Schenker, M., additional, Chiarion-Sileni, V., additional, Marquez-Rodas, I., additional, Grob, J.-J., additional, Butler, M., additional, Middleton, M.R., additional, Maio, M., additional, Atkinson, V., additional, Dummer, R., additional, de Pril, V., additional, Qureshi, A., additional, Larkin, J., additional, and Ascierto, P.A., additional

Published
2018
Full Text
View/download PDF

35. Anti-CTLA4 toxicity associates with genetic variation correlating with serum antibody diversity

Author

Simpson, D., primary, Ferguson, R., additional, Gowen, M., additional, Giles, K.M., additional, Tchack, J., additional, Zhou, H., additional, Moran, U., additional, Dawood, Z., additional, Pavlick, A., additional, Hu, S., additional, Wilson, M.A., additional, Zhong, H., additional, Krogsgaard, M., additional, Weber, J.S., additional, Osman, I., additional, and Kirchhoff, T., additional

Published
2018
Full Text
View/download PDF

37. Survie à 3 ans des patients traités pour mélanome métastatique par prembrolizumab (Keynote-001) et devenir des patients en réponse complète

Author

Robert, C., primary, Ribas, A., additional, Hamid, O., additional, Daud, A., additional, Wolchok, J.D., additional, Joshua, A.M., additional, Hwu, W.-J., additional, Weber, J.S., additional, Gangadhar, T.C., additional, Joseph, R., additional, Dronca, R., additional, Patnaik, A., additional, Zarour, H., additional, Kefford, R., additional, Hersey, P., additional, Li, X.N., additional, Diede, S.J., additional, Ebbinghaus, S., additional, and Hodi, S., additional

Published
2016
Full Text
View/download PDF

42. 1310O - Adjuvant nivolumab (NIVO) versus ipilimumab (IPI) in resected stage III/IV melanoma: 3-year efficacy and biomarker results from the phase III CheckMate 238 trial

Author

Weber, J.S., Del Vecchio, M., Mandala, M., Gogas, H., Arance, A.M., Dalle, S., Cowey, C.L., Schenker, M., Grob, J.J., Chiarion-Sileni, V., Marquez-Rodas, I., Butler, M.O., Maio, M., Middleton, M.R., Tang, T., Saci, A., De Pril, V., Lobo, M., Larkin, J.M.G., and Ascierto, P.A.

Published
2019
Full Text
View/download PDF

44. melanoma and other skin tumours Ipilimumab (IPI) vs placebo (PBO) after complete resection of stage III melanoma: final overall survival results from the EORTC 18071 randomized, double-blind, phase 3 trial

Author

Eggermont, A.M.M., primary, Chiarion-Sileni, V., additional, Grob, J.-J., additional, Dummer, R., additional, Wolchok, J.D., additional, Schmidt, H., additional, Hamid, O., additional, Robert, C., additional, Ascierto, P.A., additional, Richards, J.M., additional, Lebbé, C., additional, Ferraresi, V., additional, Smylie, M., additional, Weber, J.S., additional, Taitt, C., additional, de Pril, V., additional, de Schaetzen, G., additional, Suciu, S., additional, and Testori, A., additional

Published
2016
Full Text
View/download PDF

47. 511 Updated results from a phase 1/2 study of epacadostat (INCB024360) in combination with ipilimumab in patients with metastatic melanoma

Author

Gibney, G., primary, Hamid, O., additional, Lutzky, J., additional, Olszanski, A., additional, Gangadhar, T., additional, Gajewski, T., additional, Chmielowski, B., additional, Hanks, B., additional, Boasberg, P., additional, Zhao, Y., additional, Newton, R., additional, Bowman, J., additional, Maleski, J., additional, Leopold, L., additional, and Weber, J.S., additional

Published
2015
Full Text
View/download PDF

48. 23LBA An open-label, randomized, phase 2 study of nivolumab (NIVO) given sequentially with ipilimumab (IPI) in patients with advanced melanoma (CheckMate 064)

Author

Hodi, F.S., primary, Gibney, G., additional, Sullivan, R., additional, Sosman, J.A., additional, Slingluff, C.L., additional, Lawrence, D.P., additional, Logan, T.F., additional, Schuchter, L.M., additional, Nair, S., additional, Fecher, L., additional, Buchbinder, E., additional, Ruisi, M., additional, Kong, G., additional, Horak, C., additional, and Weber, J.S., additional

Published
2015
Full Text
View/download PDF

49. P0116 Updated clinical efficacy of the anti-PD-1 monoclonal antibody pembrolizumab (MK-3475) in 411 patients with melanoma

Author

Ribas, A., primary, Wolchok, J.D., additional, Robert, C., additional, Kefford, R., additional, Hamid, O., additional, Daud, A., additional, Hwu, W-J., additional, Weber, J.S., additional, Joshua, A.M., additional, Gangadhar, T.C., additional, Patnaik, A., additional, Hersey, P., additional, Dronca, R., additional, Zarour, H., additional, Gergich, K., additional, Lindia, J.A., additional, Giannotti, M., additional, Li, X.N., additional, Ebbinghaus, S., additional, Kang, S.P., additional, and Hodi, F.S., additional

Published
2015
Full Text
View/download PDF

50. 140 Relationship between programmed death ligand 1 (PD-L1) expression and clinical outcome in patients (pts) with melanoma (MEL) treated with pembrolizumab (pembro; MK-3475)

Author

Daud, A., primary, Hamid, O., additional, Robert, C., additional, Hodi, F.S., additional, Wolchok, J.D., additional, Hwu, W.J., additional, Weber, J.S., additional, Kefford, R., additional, Hersey, P., additional, Joshua, A.M., additional, Joseph, R., additional, Gangadhar, T.C., additional, Dronca, R., additional, Patnaik, A., additional, Zarour, H., additional, Gerigich, K., additional, Lunceford, J., additional, Emancipator, K., additional, Dolled-Filhart, M., additional, Li, X., additional, Kang, P., additional, Ebbinghaus, S., additional, and Ribas, A., additional

Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results